Rapid Recurrence ofHelicobacter pyloriInfection in Peruvian Patients after Successful Eradication
| Autor: | Sixto Recavarren-Arce, Robert H. Gilman, Juan Carrazco, Luis Cordero, Guillermo Salazar, Alberto Ramírez-Ramos, Jeff McDonald, Jose Watanabe, Raul Leon-Barua, William Checkley, Yanet Valdez |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty biology business.industry Spirillaceae Cancer macromolecular substances Helicobacter pylori Amoxicillin biology.organism_classification medicine.disease Gastroenterology Bismuth subsalicylate Surgery Regimen Infectious Diseases Internal medicine medicine Gastritis medicine.symptom business Antibacterial agent medicine.drug |
| Zdroj: | Clinical Infectious Diseases. 25:1027-1031 |
| ISSN: | 1537-6591 1058-4838 |
| Popis: | Helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer. Since gastric cancer is common in Peru, eradication of H. pylori may help to reduce the occurrence of gastric cancer. This study involved three randomized trials to determine the efficacy of four different triple-drug therapy regimens. The most successful regimen was furazolidone combined with bismuth subsalicylate and amoxicillin, which eradicated infection in 82% of patients. Patients successfully treated were followed every 2-3 months to determine the recurrence rate of H. pylon infection. Of 105 patients with H. pylon eradication documented by pathology and culture, 52% (55) returned for follow-up endoscopy, and in 73% (40) of these 55 the infection recurred during the 8-month follow-up period. Thirty-five patients from whom H. pylori was eradicated and who were tested for antibodies to H. pylori remained consistently seropositive. Rapid recurrence of H. pylori infection after successful eradication suggests that measures other than antimicrobial therapy are needed to fight H. pylori in developing countries. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|